Broome Oncology

Renal Cancer News

FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer (February 18, 2019)

The Food and Drug Administration (FDA) approved the immunotherapy drugs Opdivo and Yervoy in combination as an initial, or first-line, treatment for patients with advanced kidney cancer whose disease has an intermediate or poor prognosis. This is the... Continue Reading

Keytruda Plus Inlyta Improves Survival Compared ot Sutent for Treatment of Advanced Kidney Cancer (February 18, 2019)

Results from the randomized, phase III KEYNOTE-426 clinical trial show that first-line therapy with a combination of the PD-1 targeted immunotherapy Keytruda (pembrolizumab) and the VEGF-targeted tyrosine kinase inhibitor Inlyta (axitinib) improved overall... Continue Reading

Personalized Vaccine to be Tested in Patients with Kidney Cancer (February 13, 2019)

By pairing a novel personalized cancer vaccine with a more established immunotherapy drug that is administered to patients in an innovative fashion, scientists at Dana-Farber Cancer Institute are testing a first-of-its-kind strategy aimed at improving... Continue Reading

Personalized Vaccine to be Tested in Patients with Kidney Cancer (January 29, 2019)

By pairing a novel personalized cancer vaccine with a more established immunotherapy drug that is administered to patients in an innovative fashion, scientists at Dana-Farber Cancer Institute are testing a first-of-its-kind strategy aimed at improving... Continue Reading

Tivozanib for Renal Cell Cancer (November 16, 2018)

The precision cancer medicine tivozanib delays cancer progression and prolongs survival in individuals with advanced renal cell cancer (RCC). About tivozanib Tivozanib is an oral vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor. In... Continue Reading

FDA Approves Opdivo plus Yervoy Combination for Advanced Kidney Cancer (April 23, 2018)

CancerConnect News: The Food and Drug Administration granted approvals to Opdivo  (nivolumab) and Yervoy (ipilimumab) in combination for the treatment of intermediate or poor risk, previously untreated advanced kidney cancer (renal cell carcinoma). About... Continue Reading

Breakthrough Therapy Designation Awarded by FDA for Lenvima and Keytruda Combination Treatment for Advanced Renal Cell Carcinoma (January 25, 2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has announced “Breakthrough Therapy Designation” for the multiple receptor tyrosine kinase inhibitor Lenvima® (lenvatinib) in combination with Keytruda® (pembrolizumab) for the potential... Continue Reading

FDA Grants Approval to Cabometyx for First-Line Treatment of Advanced Renal Cell Carcinoma (January 5, 2018)

CancerConnect News: The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma... Continue Reading

Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer (November 9, 2017)

Opdivo (nivolumab) a novel “checkpoint” inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC).1 Treatment options for RCC continue to... Continue Reading

Latest Renal Cancer News By Stage


General Renal Cancer

Sorry, there are no articles available for this cancer stage.

More General Renal Cancer